Navigation Links
MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
Date:10/29/2010

triptan analyses. Factors found to affect the rate of recurrence in the triptan meta-analyses include gender of the patient, age group (below 35 and above 35), and severity of headache pain at the time of treatment (moderate vs. severe). In this analysis, both age and severity of pain at time of treatment were associated with higher recurrence rates in the placebo group.

A second new analysis, "The Major Metabolite of Dihydroergotamine (DHE) After Oral Inhalation and IV Administration Does Not Significantly Contribute to the Pharmacological Activity," analyzed results of two studies and showed that the pharmacologic contribution of DHE's primary metabolite is minimal.

The seven other analyses to be presented include:

  • LEVADEX, a Novel Orally Inhaled Treatment for Acute Migraine: Efficacy and Tolerability Results of a Phase 3 Study (#462)
  • Efficacy Evaluation of LEVADEX in Treating a Broad Spectrum of Acute Migraine Attacks (#463)
  • Efficacy Evaluation of LEVADEX in Treating Resistant Migraine Including Migraine with Allodynia, Morning Migraine, Disabling Migraine and Migraine Treated Late (#464)
  • Utility of LEVADEX in Situations Where Early Intervention Paradigm is Impractical (#322)
  • Evaluation of Safety and Efficacy of LEVADEX (MAP0004) in Treating Acute Menstrual Migraine (#465)
  • Evaluation of Efficacy and Safety of LEVADEX (MAP0004) in Reversing Central Sensitization and Treating Migraine in Established Allodynic Patients (#466)
  • The Efficacy and Tolerability of LEVADEX (Orally Inhaled DHE) for the Treatment of Migraine in Subjects with Concomitant Asthma (#467)

  • About LEVADEX™ LEVADEX orally inhaled migraine therapy is a novel migraine therapy in Phase 3 development. Patients administer LEVADEX themselves using the company's proprietary TEMPO® inhaler. LEVADEX has been designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergot
    '/>"/>

    SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... , Aug. 20, 2014 The National Necrotizing ... Fernando Davila has been successfully treated for a life ... Dr, Anibal R. Gauto , Medical Director of Inpatient ... Eisenhower Medical Center in Rancho Mirage, California ... pioneered by Dr. John Crew at Seton Hospital ...
    (Date:8/20/2014)... 2014 Research and Markets  has announced the ... report to their offering. Global Market Report ... Pralmorelin globally and regionally ( Europe , ... Latin America etc.). It captures Pralmorelin ... report focuses on three primary areas; manufacture methods & technology ...
    (Date:8/20/2014)... , Aug. 20, 2014 Research ... the "Global Advanced Wound Care and Closure ... Size, Share, Global Trends, Company Profiles, Demand, Insights, ... - 2020" report to their offering. ... wound care and closure market (types, applications, end ...
    Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
    ... Germany, January 18, 2012 Eppendorf AG ... to Bibby Scientific for use e.g. in their TC ... 7,074,367. Eppendorf utilizes the technology in its Eppendorf Mastercycler® ... models. Eppendorf AG, based in Hamburg, Germany, ...
    ... Takeda Pharmaceutical Company Limited ("Takeda", TSE: ... global workforce and consolidate site operations in order to ... than 70 countries, adapt to changing market conditions and ... as outlined in its 2011-2013 Mid-Range Plan (MRP). ...
    Cached Medicine Technology:Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 2Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 3Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 4Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth 5
    (Date:8/20/2014)... -- Pigs, hearts transplanted into baboons survived for more ... previously achieved, researchers report. The work is part ... to shorten transplant waiting lists. In this study, ... abdomens. The genetic engineering and new methods of suppressing ... hearts to survive for more than a year. ...
    (Date:8/20/2014)... Kathleen Doheny HealthDay Reporter ... a mastectomy has long been an option, but a new ... it. "The most common reasons women didn,t undergo reconstruction ... in more surgery or they were focused on their cancer ... surgery at Memorial Sloan Kettering Cancer Center, in New York ...
    (Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
    (Date:8/20/2014)... cause of endophthalmitis, a potentially blinding condition that can ... are the well-known staphylococci ("staph") and ... published in the August issue of Ophthalmology ... cases at New York Eye and Ear Infirmary of ... that gram-positive bacteria, which include staph and strep infections, ...
    (Date:8/20/2014)... Reinberg HealthDay Reporter TUESDAY, ... that dismantles a baby,s immune system is twice as common ... million infants says. This is the first evaluation of ... condition known as severe combined immunodeficiency (SCID), or "Bubble Boy" ... this condition by the boy in the bubble, who was ...
    Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3
    ... in the search for new Alzheimer,s,drugs, BIRMINGHAM, ... not-for-profit organization that conducts basic and applied,research in ... development --,today announced it has received funding from ... small molecules that activate Nuclear,Factor-kB (NF-kB)--a transcription factor ...
    ... -, NEW YORK, Oct. 1 American Media, Inc. (AMI) ... Form 10-Q,for the quarterly period ended June 30, 2007. In the ... first quarter of fiscal 2007 were $121.8 million, as ... 2006, representing a 5.6% increase., ...
    ... A visionary leader, Dr.,Maria Cristina Escobar Fritzsche ... contributions to the prevention and control of ... Pan American Sanitary Conference,proceedings today. The Abraham ... bestowed upon creative leaders whose commitment to,public ...
    ... 1. Organizations Issue Comprehensive Guidelines for Treating Low Back Pain ... , (Clinical Guidelines, p. 487.) (NOTE: This article is ... A separate news release will be issued.) , ... at Suppressing Hepatitis B Virus , A 52-week, randomized ...
    ... Flextronics International,Ltd. (Nasdaq: FLEX ) announced ... Corporation (NYSE: SLR ) creating the most ... vertically integrated,electronics manufacturing services ("EMS"). As a ... worldwide,EMS capabilities, from design resources to end-to-end vertically ...
    ... has named Glenn Adriance as Vice President of ... proven track record of developing, implementing,and managing effective ... "Glenn brings a wealth of experience to ... am pleased to welcome Glenn to the Mesa ...
    Cached Medicine News:Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 2Health News:Southern Research Institute's Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding 3Health News:American Media Operations, Inc. Files Form 10-Q For First Quarter 2007 2Health News:Inter-American Leadership Award Bestowed Upon Chilean Chronic Disease Expert 2Health News:Annals of Internal Medicine tip sheet for Oct. 2 2Health News:Flextronics Completes Acquisition of Solectron 2Health News:Flextronics Completes Acquisition of Solectron 3Health News:Flextronics Completes Acquisition of Solectron 4Health News:Flextronics Completes Acquisition of Solectron 5
    The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
    The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
    The ImagingPlanet 55 mm Surgical Microscope Adapter. Superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical micro...
    The DEI 750 MD from Optronics is a surgical 3 CCD color microscope camera with a 10 meter head cable. Easily mounts on your microscopes C-mount adapter and is the best choice for your surgical imagin...
    Medicine Products: